JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Co-Diagnostics Inc

Fechado

SetorSaúde

0.25 19.05

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.21

Máximo

0.25

Indicadores-chave

By Trading Economics

Rendimento

3.5M

-7.5M

Vendas

-99K

50K

Margem de lucro

-14,983.533

Funcionários

132

EBITDA

4.3M

-7.2M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+300% upside

Dividendos

By Dow Jones

Próximos Ganhos

14 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-2.1M

9.4M

Abertura anterior

-18.8

Fecho anterior

0.25

Sentimento de Notícias

By Acuity

50%

50%

175 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Co-Diagnostics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2025, 21:42 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 de ago. de 2025, 21:21 UTC

Ganhos
Grandes Movimentos do Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 de ago. de 2025, 20:45 UTC

Ganhos

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 de ago. de 2025, 19:15 UTC

Grandes Movimentos do Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 de ago. de 2025, 23:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de ago. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 de ago. de 2025, 23:28 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

4 de ago. de 2025, 23:28 UTC

Conversa de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 de ago. de 2025, 21:30 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 de ago. de 2025, 21:21 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 de ago. de 2025, 21:18 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 de ago. de 2025, 20:25 UTC

Conversa de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 de ago. de 2025, 20:25 UTC

Ganhos

Transocean 2Q Loss $938M >RIG

4 de ago. de 2025, 20:25 UTC

Ganhos

Transocean 2Q Loss/Shr $1.06 >RIG

4 de ago. de 2025, 20:18 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 de ago. de 2025, 20:15 UTC

Ganhos

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 de ago. de 2025, 20:13 UTC

Ganhos

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 de ago. de 2025, 20:09 UTC

Ganhos

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 de ago. de 2025, 20:06 UTC

Ganhos

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 de ago. de 2025, 19:41 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 de ago. de 2025, 19:28 UTC

Conversa de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 de ago. de 2025, 19:07 UTC

Conversa de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 de ago. de 2025, 18:27 UTC

Conversa de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparação entre Pares

Variação de preço

Co-Diagnostics Inc Previsão

Preço-alvo

By TipRanks

300% parte superior

Previsão para 12 meses

Média 1 USD  300%

Máximo 1 USD

Mínimo 1 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Co-Diagnostics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

0

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.3495 / 0.3699Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

175 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Co-Diagnostics Inc

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.